BriaCell Therapeutics Corp. (BCTX), a clinical-stage biotechnology company, on Tuesday reported durable and sustained complete resolution of a lung metastasis in a patient with metastatic breast cancer treated with its off-the-shelf immunotherapy candidate Bria-OTS.
Following the promising report for Bria-OTS, BCTX shares surged 50% to $11 in the pre-market.
The first patient enrolled in the Phase 1/2a Bria-OTS study, a 78-year-old woman with advanced metastatic breast cancer and multiple prior treatment failures and hormone receptor-positive (HR+), HER2-negative, achieved complete (100%) resolution of a lung metastasis following four doses of Bria-OTS single agent therapy.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.